| Model Number |
EVPROPLUS-34US |
| Medical Device Problem Codes |
Patient Device Interaction Problem (4001); Thickening of Material (4056); Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Codes |
Calcium Deposits/Calcification (1758); Low Cardiac Output (2501); Aortic Valve Insufficiency/ Regurgitation (4450); Pulmonary Valve Insufficiency/ Regurgitation (4452)
|
| Date of Event |
06/02/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Corrected data: h6.Annex a code a040612 was added.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b7.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
It was reported that approximately 5 years and 6 months following the implant of a transcatheter aortic valve, the valve failed due to severe central aortic regurgitation and calcified leaflets.Moderately decreased ejection fraction and mild pulmonary regurgitation were also observed via echocardiogram.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|